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Preface: The Quality Assurance subcommittee of the ACMG
Laboratory Practice committee has the mission of maintaining
high technical standards for the performance and interpretation
of genetic tests. In part, this is accomplished by the publication of
the document “Standards and Guidelines for Clinical Genetics
Laboratories,” which was published in its second edition in 1999
andisnowmaintainedonline(seewww.faseb.org/genetics/acmg/
index.html). This subcommittee also reviews the outcome of na-
tional proficiency testing in the genetics area and may choose to
focus on specific diseases or methodologies in response to those
results. Accordingly, the subcommittee selected fragile X syn-
drometobethefirsttopicinanewseriesofsupplementalsections,
recognizing that it is one of the most frequently ordered genetic
tests and that it has many alternative methods with different
strengths and weaknesses. This document follows the outline for-
mat of the general Standards and Guidelines. It is designed to be
achecklistforgenetictestingprofessionalswhoarealreadyfamil-
iar with the disease and the methods of analysis.
1 INTRODUCTION
Disease-specific statements are intended to augment the
current general ACMG Standards and Guidelines for Clinical
Genetics Laboratories. Individual laboratories are responsible
for meeting the CLIA/CAP quality assurance standards with
respect to appropriate sample documentation, assay valida-
tion, general proficiency, and quality control measures.
2 BACKGROUND ON FRAGILE X SYNDROME
2.1 Gene symbol/chromosome locus: FMR1; also FRAXA.
2.2 OMIM number: 309550.
2.3 Brief clinical description: The features of fragile X syn-
dromeincludementalretardationandcertaincharacteristic
but nonspecific physical features and behaviors. For more
information see the online Gene Clinics profile at www.ge-
neclinics.org and the National Fragile X Foundation at
www.nfxf.org.
2.4 Mode of inheritance: Inheritance is X-linked but is also
notable for the presence of unaffected male carriers. In typical
fragile X families, the mutation is a multi-step expansion in a
region of CGG repeats. Small expansions (premutations) are
generally silent in both males and females. Large expansions
(full mutations) are penetrant in all males and many females.
Withextremelyrareexceptions,onlyfemalescanhaveaffected
children.
2.5 Gene description/normal gene product: The gene product
is FMRP, fragile X mental retardation protein, a widely ex-
pressed RNA-binding protein of unknown function found at
highest levels in the brain and testes.
2.6Mutationalmechanism/abnormalgeneproduct:Fragile
XsyndromeiscausedbythedeficiencyorabsenceofFMRP.
Theoretically, this can occur through any type of deletion
orinactivatingmutation,butinwellover99%ofcasesthere
is an expansion of a segment of CGG repeats in the 5' UT
region of FMR1. Large CGG expansions in this region
are associated with hypermethylation and inhibition of
transcription.
2.7 Listing of mutations: Mutations at locations other than
the CGG repeat have been described. A listing can be found in
the Human Gene Mutation Database at www.uwcm.ac.uk/
uwcm/mg/hgmd0.html. Guidelines for detecting these rela-
tively rare mutations are beyond the scope of this document.
2.8Ethnicassociationofcommonmutations:Allmajorethnic
groups appear to be susceptible to expansion of the FMR1
CGG region.
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2.9.1 Sensitivity and specificity: CGG-repeat expansion mu-
tations account for .99% of cases of fragile X syndrome.
Therefore, tests that effectively detect and measure the CGG-
repeat region of the FMR1 gene are .99% sensitive. Positive
results are 100% specific, although a gray zone of CGG repeat
sizes has been defined where the significance of carrier test
results is inconclusive (see section 3.1.2). There are no known
forms of FMRP deficiency that do not map to the FMR1 gene.
FragileXsyndromeshouldnotbeconfusedwiththeunrelated
mental retardation syndrome associated with the FRAXE
locus.
2.9.2 Diagnostic versus predictive testing: This test is used for
confirmative diagnosis and carrier detection. Positive results
are considered diagnostic rather than predictive, inasmuch as
penetranceisvirtually100%inmalesandtheageofonsetisnot
variable.
2.9.3 Prenatal testing: This test can be used for prenatal di-
agnosis in both amniotic fluid cells and chorionic villus sam-
ples(CVS).LaboratoriesofferingCVStestingmustbeawareof
thistissue’suniqueproperties.(a)Methylationassociatedwith
lyonization is usually not present, and methylation associated
withfullmutationsmayormaynotbepresent.Inthepast,the
hypomethylated status of this locus in this tissue had been
thought of as a limitation or possible source of confusion. To
thecontrary,becauseitisunwarrantedtousemethylationsta-
tus or X-inactivation for phenotypic prediction of a full muta-
tion, the possible hypomethylation of this tissue is no disad-
vantage, provided that the tissue-specific basis of the
hypomethylation is understood. It is an acceptable option to
omit methylation analysis entirely when testing CVS speci-
mens. In the minor fraction of CVS cases with a result that is
ambiguous between a large premutation and a small full mu-
tation by size criteria alone, a follow-up amniocentesis may be
required.(b)Thedegreeofsomaticvariationinafullmutation
“smear” has a wider range of possibilities than is typically seen
in blood specimens, from very limited to extraordinarily dif-
fuse. (c) Mosaicism between trophoblasts and somatic cells is
theoretically possible. For this reason, when CVS results indi-
cate a premutation, follow-up amniocentesis has been sug-
gested to rule out mosaicism for a full mutation; however,
there is no known occurrence of this type of mosaicism.
3 GUIDELINES
3.1 Definition of normal and mutation categories
3.1.1 Normal alleles have a range of ~5 to ~44. The most
common length by far is 29 or 30 CGG repeats. Normal alleles
have no meiotic or mitotic instability.
3.1.1.1 In stable normal alleles, the CGG region is inter-
rupted by an AGG triplet after every 9 or 10 CGG repeats. The
AGG triplets are thought to anchor the region during replica-
tion and prevent strand slippage. Direct testing for the AGG
triplets is not routinely performed.
3.1.2 The range from ~45 to ~54 is a Gray Zone (Interme-
diate, Inconclusive, Borderline). Alleles in this range can be
considered normal in the sense that women with alleles of this
size have not been observed to have affected children. On the
other hand, alleles of this size may be associated with fragile X
syndrome in future generations or in distant relatives. Minor
increases and decreases in repeat number can occur when al-
lelesofthissizearepassedon,butthereisnomeasurableriskof
anaffectedchildinthenextgeneration.Allelesinthisrangecan
be referred to as premutations if they are confirmed by family
studies to be traceable to a known full mutation or unambig-
uous premutation.
3.1.3 Premutation alleles range from ~55 to ~200 repeats.
They show no somatic variation. They are not hypermethyl-
ated and are not associated with mental retardation. Women
with alleles in this range are considered to be at risk for having
affected children, although to date all known mothers of af-
fected children have alleles of 59 repeats or higher.
3.1.3.1Theupperlimitofpremutationsissometimessaidto
be ~230. In fact, both numbers (200 and 230) are rough esti-
mates derived from Southern blots where large premutations
were measured with increases of 0.5 to 0.6 kb, implying
roughly 170 to 200 more triplet repeats than normal.
3.1.4Fullmutationshaveover230repeats,typicallyseveral
hundred to several thousand repeats. There is usually broad
somatic variation within each patient. Hypermethylation is
typically present on most or all copies. The appearance of full
mutationsmayvaryinCVS,comparedwithbloodandamnio-
cytes: methylation may or may not be present, and the degree
of somatic heterogeneity ranges from distinctly limited to ex-
traordinarily diffuse.
3.1.5Mosaicismduetodenovosomaticmutationsdoesnot
occur at the FMR1 CGG-repeat region, but size mosaics and
methylation mosaics have been observed. When mosaicism is
present, tissue-specific differences can be seen.
3.1.5.1 Size mosaics: This term refers to subpopulations of
full mutations and premutations. Occasionally there also may
be minor subpopulations with near normal or subnormal
length.
3.1.5.2 Methylation mosaics: This term refers to full muta-
tions with subpopulations that remain unmethylated.
3.2 METHODOLOGICAL CONSIDERATIONS
All general guidelines for Southern blots and polymerase
chain reaction (PCR) in the ACMG Standards and Guidelines
apply.ThefollowingadditionaldetailsarespecificforfragileX.
For this test, there are many valid methods with different
strengths and weaknesses. Laboratories very often need to use
morethanonemethodbecausenosinglemethodcandetectall
types of mutations equally well or with equal precision. When
a given method is recognized to have certain weaknesses, it is
assumed that a complementary method will also be used.
3.2.1 Southern blots
3.2.1.1 Probe and restriction site combinations
Several single- and double-enzyme options are commonly
used, and several probes are available (Table 1).1–4 Other re-
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demonstrated.
3.2.1.2 In general, small premutations are more easily de-
tected when the normal fragment is small and/or electro-
phoretic migration is long, whereas large/diffuse full muta-
tions are more easily detected when the normal fragment is
large and/or electrophoretic migration is short.
3.2.1.3 Controls should be included to confirm the proper
choice and activity of restriction enzymes and probe, and ide-
ally should represent the more difficult-to-recognize geno-
types.Toverifydigestionandhybridizationparameters,anor-
mal control will suffice. However, in fragile X blots the
abnormal controls are extremely important because they pro-
vide quality control on the resolution of small premutations
and the detectability of diffuse smears.
3.2.1.4 For female patients, it should be noted that the de-
gree of separation between two differently sized normal alleles
could appear identical with that between a normal and a pre-
mutationallele(e.g.,20and44repeatsvs.35and59repeats).A
Southern blot with superior resolution and appropriate size
standards or controls is required to distinguish between these
possibilities. Alternatively, most PCR-based methods can pro-
vide the required resolution. Similar considerations apply to
detectionofpremutationallelesinnormaltransmittingmales.
3.2.1.5 Because full mutations can be extremely diffuse and
faint, signal:noise ratios must be very good. Laboratories are
advised to be aware of the many different appearances of full
mutations. Full mutations are not likely to be overlooked in
males,inasmuchasthenormalsignalwillbeabsent(orlight,in
size mosaics), but full mutations can be easily missed in fe-
males if the background is poor.
3.2.1.6 Migration distances should be interpreted using a
standard ladder such as lambda HindIII fragments or a set of
carefully chosen, independently tested human references.
3.2.1.7 The following guidelines refer to methylation analy-
sis using double digestion.
3.2.1.7.1 In tissues other than CVS, methylation analysis re-
veals the degree of hypermethylation in full mutations and
shows the distribution of X-inactivation in any female with
two distinguishable alleles. Neither type of methylation infor-
mation is necessary for the interpretation of results, but detec-
tion of methylation can help discriminate between premuta-
tions and full mutations for the rare alleles that fall near the
boundary, i.e., around 200 repeats.
3.2.1.7.2 In tissues other than CVS, methylation analysis
confirms the chromosomal gender of patients, which may be
useful for quality assurance. It also detects 46,X and 47,XXY
subjects indirectly.
3.2.1.7.3 In tissues other than CVS, methylation analysis in-
creases the difficulty of detecting females with small premuta-
tions who have highly skewed X-inactivation. Double diges-
tion with a methyl-sensitive enzyme causes the signal from
eachalleleinafemaletobesplitintoactiveandinactivebands,
formingfourbandsinacarrierfemale.WhenX-inactivationis
balanced in a carrier the two active bands are readily seen,
although the two inactive bands may comigrate. However, if
X-inactivation is heavily skewed, there will be only two visible
bands.Thisisparticularlychallengingwhenthepremutationis
predominantly inactive, because then it appears only in the
upper region of the gel where resolution is considerably
poorer. For an example of a carrier with extremely skewed
X-inactivation, see Figure 1, lane 13. Lanes 3 and 4 show two
females with oppositely skewed X-inactivation.
3.2.1.7.4 In CVS tissue, the FMR1 region usually does not
havemethylationassociatedwithX-inactivation,anditmayor
may not have hypermethylation associated with full muta-
tions. When testing CVS tissue, methylation analysis is op-
tional.Ifdone,itshouldneverbeusedtopredicttheseverityof
a full mutation or the influence of X-inactivation.
Incidentally,methylationanalysiscanserendipitouslyalerta
laboratory to maternal cell contamination in chorionic villus
Table 1
Probe and restriction site combinations
Primary restriction sites
and normal length
Optional internal
methyl-sensitive sites Probes and references
EcoRI, 5.2 kb
HindIII, 5.4 kb
BglII, 12 kb
EagI, BssHI, NruI, etc. StB12.3 (1), E5.1 (2),
Ox1.9 (3)
PstI, 1.0 kb n/a pfxa3 (4), Ox0.55 (3)
Fig. 1 Southern blot using EcoRI and EagI digestion, probed with StB12.3, using ex-
tended electrophoresis to illustrate several subtle specimen types. (1) Normal female. (2)
Full mutation male. Note the combination of a predominant band with a diffuse smear.
(3)Femalewith28and52repeats,withthesmallerallelepredominantlyactive.(4)Female
with26and52repeats,withthelargerallelepredominantlyactive.(5)Femalewith18and
~80 repeats, with equal X-inactivation. (6) Normal male. (7) Normal male, underloaded
and smiling due to DNA degradation. (The apparent line between lane 6 and 7 is a
photographic artifact.) (8) Normal female. (9) Normal male. (10) Normal male. (11)
Affectedmale,underloadedandverydiffuse.(12)Premutationmale.(13)Femalewith20
and 70 repeats, with the smaller allele virtually exclusively active. The only evidence of
abnormality is the slow migration of the “5.2 kb” band. (14) Female with 27 and 42
repeats, with the larger allele somewhat more active. (15–17) Unremarkable normal fe-
males and male. Figure provided by Genetics & IVF Institute.
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vationisusuallynotpresentatthislocusinCVStissue,astrong
normal inactive band can be a sign of possible maternal cell
contamination. Other explanations for such a band include
X-inactivationinsomefetalcellsorincompletedigestion.Fur-
ther investigation would be called for.
3.2.2 PCR methods
3.2.2.1 Several sets of primers, PCR conditions, and meth-
odsofseparationanddetectionhavebeenpublished.5–8Other
primers and methods can be used if equivalence is demon-
strated. A particular region to be aware of in primer design is
the deletional hotspot.
3.2.2.2AllPCRreactions,foranylocus,cantheoreticallyfail
todetectanalleleifthereispolymorphismataprimerbinding
site.Therearenoknownpolymorphismsthatwouldaffectany
of the commonly used primers.
3.2.2.3 Patient amplicon sizes should be determined using a
standardladdersuchasanM13sequencingreactionorasetof
carefully chosen, independently tested human references.
3.2.2.4 Controls representing the genotypes to be distin-
guishedshouldberunoneachgel.Theupperlimitofallelesize
that can be successfully detected should be known, and a con-
trol corresponding to that size should be included in each run.
Laboratories should confirm the size of their control DNA by
sequencing or by exchange with another laboratory.
3.2.2.5 Amplification of CG-rich regions is difficult, and
special conditions are required. The difficulty increases with
increasing numbers of CGG repeats; therefore, many PCR
strategies do not attempt to detect large alleles. In such a sys-
tem, it is not possible to tell the difference between a female
whoishomozygousforanormalalleleandonewhohasalarge
nonamplifiable second allele. Similarly, patients who are mo-
saics for premutations and full mutations will appear to have
only premutations.
3.2.2.6 When a PCR strategy is capable of detecting large
alleles, amplification nevertheless may favor the smaller allele
inanyspecimenwithmultiplealleles,i.e.,femalesandmosaics.
Such methods should be validated with carrier females and
mosaics,inadditiontomales.Becauseofdisproportionateam-
plification, PCR is not reliable for determining the ratio of
different species in a mosaic individual.
3.2.2.7InPCRamplificationoffemalesandmosaics,hetero-
duplexes can form. If denaturing electrophoresis is used, con-
ditions must be sufficiently denaturing to avoid heteroduplex
artifact. If nondenaturing electrophoresis is used, steps must
be taken to distinguish between heteroduplexes and true ab-
normal alleles.
3.2.2.8 Basic PCR amplification is not affected by methyl-
ation.AlthoughPCRtestsspecificallymodifiedtodetectmeth-
ylation status have been described,9,10 the common PCR strat-
egies that have been in use for many years are completely
independent of methylation.
3.2.2.9WhenaPCRstrategyisusedtodetectfullmutations,
the presence of a deletion hotspot in the CGG-repeat region
shouldbenoted.11Primerslocatedwithinthedeletionhotspot
may result in failure to detect the expanded allele. Primers
located upstream of the deletion hotspot may result in appar-
ent size mosaicism.
3.3 INTERPRETATIONS
3.3.1 The following elements must be included in the re-
port, in addition to the items described in the current general
Standards and Guidelines.
3.3.1.1 State whether the method used was PCR, Southern
blot, or both. If Southern blot, state the restriction enzymes
and probes used. If PCR, state the method used for separation
and detection.
3.3.1.2 State the definitions used for normal, gray-zone
(borderline, inconclusive) premutation, and full mutation.
3.3.1.2.1 Note that it is not necessarily obvious that the bor-
derline category refers to the border between normal and pre-
mutation,andnottotheborderbetweenpremutationandfull
mutation. Similarly, note that the term instability, which is
often used with regard to borderline alleles to describe minor
intergenerationalormitoticchanges,mayunintentionallysug-
gest a risk of having an affected child or personal late-onset
symptoms.
3.3.1.3 Classify the patient’s result using the defined catego-
ries. The term size mosaic should be used for alleles that have
significant subpopulations in both the premutation and full
mutation range.
3.3.1.4 All positive results should state that genetic counsel-
ing is indicated and testing is appropriate for at-risk family
members.
3.3.2Thefollowingdescriptiveelementsmayappear,with
caution.
3.3.2.1 The size of the alleles may be reported. If so, the
precision used in quoting the size must be supportable by the
precision of the ladder used, the sharpness of the bands or
peaks, degree of stutter, etc. It may be appropriate to state a
range or use qualifying terms such as approximately. Descrip-
tions such as “positive for an allele with 55–200 repeats” are
ambiguous.
3.3.2.2 Description of methylation may be provided. The
two kinds of methylation must be clearly distinguished: meth-
ylation due to X-inactivation and hypermethylation of full
mutations.Thetermmethylationmosaicorincompletemethyl-
ation may be used if not all molecules in a full mutation are
hypermethylated.
3.3.3 The following helpful points on alternative diag-
nosesmaybeincluded.
3.3.3.1 There are rare forms of FMRP deficiency not caused
by CGG expansion, which may not be detected by this test.
3.3.3.2Mentalretardationassociatedwithotherfragilesites,
in particular FRAXE, will not be detected with this test.
3.3.3.3 Routine chromosome analysis is recommended in
the diagnostic workup of mental retardation.
3.3.4 Comments on phenotype, if included, should be ab-
stractratherthancase-specific.Thefollowingconceptsapply.
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drome to some degree. The severity cannot be predicted from
the size of the full mutation, but if premutations are also
present or if the majority of the full mutation molecules are
unmethylated, the phenotype MAY be less severe.
3.3.4.2Femaleswithfullmutationshaveawidespectrumof
phenotypes ranging from as severely affected as a male (which
is itself a range) to very mild or undetectable. The severity
cannotbepredictedfromthesizeofthefullmutation,norcan
it be predicted from the pattern of X-inactivation.
3.3.4.3Individualswithpremutationsshouldbeinterpreted
as unaffected carriers. The only clearly established effect asso-
ciated with premutations is a tendency in some women for
premature ovarian failure.12 If a premutation is found in a
developmentallydelayedpatient,itmustbeconsideredacoin-
cidence unless FMRP deficiency or mosaicism for a full muta-
tion can be found.
3.3.4.4 Individuals with gray-zone alleles should be inter-
pretedasunaffected.Evenmoresothanapremutation,agray-
zone allele is considered a coincidence when found in a devel-
opmentally delayed patient. FMRP deficiency or mosaicism
forafullmutationcanbeinvestigated,butwithlesslikelihood
of success because gray-zone alleles are not uncommon in the
general population.
3.3.5 Comments on reproductive risk, if included, should
be abstract rather than case-specific. The following concepts
apply.
3.3.5.1 All affected males and the overwhelming majority of
affected females inherit their mutations from their mothers.
The mothers may have premutations or full mutations.
3.3.5.2 Women with full mutations have a theoretical 50%
chance of passing on the full mutation with each pregnancy.
3.3.5.3 Women with premutations have a theoretical 50%
chanceofpassingontheabnormalXwitheachpregnancy.Ifit
is passed on, the chance the allele will increase to a full muta-
tiondependsonitssizeinthemother.Probabilitiesrangefrom
“too rare to measure” for maternal alleles in the mid 50s to
nearly100%formaternalallelesof90andabove.Theabsolute
allele size at which risk begins, and what that minimal risk is,
arenotclearlyknown.Laboratoriesshouldbefamiliarwiththe
dataofFuetal.5andNolinetal.13andanycurrentpublications
on this topic.
3.3.5.4 Men with premutations will almost always pass pre-
mutationstoalloftheirdaughters.Anextremelyrarephenom-
enon involves unaffected males with premutations who have
had affected daughters, apparently by gonadal mosaicism for
full mutations. The sons of men with premutations are not at
risk.
3.3.5.5 Men and women alike with gray-zone alleles are not
known to have affected children in the next generation. Their
status as carriers depends in part on whether the allele can be
traced through the family to a known full mutation or unam-
biguous premutation. In the absence of such a connection, on
a research basis it may be possible to show mitotic instability
and/or loss of the AGG interruptions, but such data have little
clinical value for predicting the risk to specific future
generations.
4 ALTERNATIVE TESTING METHODS
4.1Cytogeneticanalysis:TestingforthefragilesiteFRAXAat
Xq27isnolongeranacceptablediagnosticmethod.Specificity
and sensitivity are both insufficient.
4.2 Protein analysis: Immunohistochemical staining for
FMRPisavaliddiagnosticmethod.Asacarriertestitislimited
to detecting full mutation carriers.
5 POLICY STATEMENTS
5.1 The American College of Medical Genetics issued a pol-
icy statement titled “Fragile X Syndrome: Diagnosis and Car-
rier Testing” in 1994 (Am J Med Genet 53:380–381). This doc-
ument is also available online at www.faseb.org/genetics/acmg/
index.html. These Standards and Guidelines are in general
agreement with that statement.
5.2In1995theAmericanCollegeofObstetricsandGynecology
issued a Committee Opinion, No. 161, on fragile X syndrome.
These Standards and Guidelines are in general agreement with
that opinion, with the exception of its recommendation for the
useofamniocentesisforprenataldiagnosis.Inexperiencedhands,
chorionic villus samples are equally reliable and offer the advan-
tageoffirst-trimesterdiagnosistowomenwhomaybeat50%risk
foranaffectedpregnancy.However,itcannotbestressedenough
that the unique properties of this tissue must be recognized.
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